Researching the role of ubiquitination and macrophage activation-related genes in hepatocellular carcinoma through a systematic study based on gene expression profiling
- 1Department of Interventional and Vascular Surgery, The Affiliated Hospital of Putian University
Abstract
Hepatocellular carcinoma (HCC) remains a formidable global health challenge, particularly in developing nations, due to its asymptomatic nature in early stages and consequent late diagnosis. This study aims to identify novel biomarkers and therapeutic targets by focusing on Ubiquitin and Macrophage Activation-Related Genes (UMARGs), which play a crucial role in modulating the tumor microenvironment. Utilizing a comprehensive bioinformatics framework, we integrated transcriptomic data from TCGA and GEO databases with gene signatures from GeneCards. Our methodology included differential gene expression analysis, Cox regression modeling, and protein interaction networking to identify key prognostic determinants and their heterogeneity across HCC molecular subtypes. The analysis revealed two distinct HCC subtypes, Cluster A and Cluster B, each with unique gene expression profiles. Immune microenvironment heterogeneity was highlighted through CIBERSORT deconvolution, showing diverse distributions across 12 cellular subsets, notably activated T cells and macrophages.Survival analysis showed that high expression of HPX was associated with better Overall survival, while high expression of MMP9 was associated with worse Overall survival, and these trends were validated in an external GEO cohort. HPX and MMP9 may serve as candidate prognostic biomarkers for Hepatocellular carcinoma, but their Biological function and clinical application value still require further experimental investigation. Despite limitations, including the lack of experimental validation and reliance on retrospective data, this study provides valuable insights into gene expression dynamics and immune characteristics associated with HCC. These findings lay the groundwork for precision oncology paradigms, facilitating the translational trajectory of these targets to optimize clinical prognosis. Future research should focus on experimental validation and the development of targeted therapies based on these molecular insights. This study underscores the potential of UMARGs in advancing HCC treatment strategies and improving patient outcomes.
Related
- DCTN2 inhibited cellular senescence through targeting TRIM21 mediated MST2 ubiquitination and activation in hepatocellular carcinoma.
- Palmatine Induces TNNT1 Ubiquitination and Degradation to Potentiate Ferroptosis Sensitivity in Hepatocellular Carcinoma
- MGST1 expression reduces ferroptosis of macrophage in pediatric asthma through tricarboxylic acid-mitochondrial damage by ALOX5 ubiquitination.
- Ciprofol induces ferroptosis and enhances anti-PD-1 efficacy via USP1-mediated GPX4 ubiquitination in hepatocellular carcinoma
- Tumor-derived annexin A1 drives lenvatinib resistance by regulating SOX2/STAT3/S100A6 feedback loop and M2 macrophage polarization in hepatocellular carcinoma
BibTeX
@article{zhang2026researching,
title = {{Researching the role of ubiquitination and macrophage activation-related genes in hepatocellular carcinoma through a systematic study based on gene expression profiling}},
author = {Chunsheng Zhang and Jianyang Peng and Zhicheng Weng and Weida Wu and Yuanzhen Lin},
journal = {Discover Oncology},
year = {2026},
month = jul,
doi = {10.1007/s12672-026-05571-3},
url = {https://doi.org/10.1007/s12672-026-05571-3},
note = {CC BY},
}
RIS
TY - JOUR
TI - Researching the role of ubiquitination and macrophage activation-related genes in hepatocellular carcinoma through a systematic study based on gene expression profiling
AU - Chunsheng Zhang
AU - Jianyang Peng
AU - Zhicheng Weng
AU - Weida Wu
AU - Yuanzhen Lin
PY - 2026
DA - 2026/07/01
JO - Discover Oncology
DO - 10.1007/s12672-026-05571-3
UR - https://doi.org/10.1007/s12672-026-05571-3
AB - Hepatocellular carcinoma (HCC) remains a formidable global health challenge, particularly in developing nations, due to its asymptomatic nature in early stages and consequent late diagnosis. This study aims to identify novel biomarkers and therapeutic targets by focusing on Ubiquitin and Macrophage Activation-Related Genes (UMARGs), which play a crucial role in modulating the tumor microenvironment. Utilizing a comprehensive bioinformatics framework, we integrated transcriptomic data from TCGA and GEO databases with gene signatures from GeneCards. Our methodology included differential gene expression analysis, Cox regression modeling, and protein interaction networking to identify key prognostic determinants and their heterogeneity across HCC molecular subtypes. The analysis revealed two distinct HCC subtypes, Cluster A and Cluster B, each with unique gene expression profiles. Immune microenvironment heterogeneity was highlighted through CIBERSORT deconvolution, showing diverse distributions across 12 cellular subsets, notably activated T cells and macrophages.Survival analysis showed that high expression of HPX was associated with better Overall survival, while high expression of MMP9 was associated with worse Overall survival, and these trends were validated in an external GEO cohort. HPX and MMP9 may serve as candidate prognostic biomarkers for Hepatocellular carcinoma, but their Biological function and clinical application value still require further experimental investigation. Despite limitations, including the lack of experimental validation and reliance on retrospective data, this study provides valuable insights into gene expression dynamics and immune characteristics associated with HCC. These findings lay the groundwork for precision oncology paradigms, facilitating the translational trajectory of these targets to optimize clinical prognosis. Future research should focus on experimental validation and the development of targeted therapies based on these molecular insights. This study underscores the potential of UMARGs in advancing HCC treatment strategies and improving patient outcomes.
SN - 2730-6011
ER -